B2PRIME
30.4.2024 14:31:33 CEST | Business Wire | Press release
B2B Prime Services SC Ltd, a multi-asset Prime of Prime liquidity provider, has achieved another significant regulatory milestone by obtaining a security dealer license in Seychelles. This marks the third license for B2Prime, following those in Cyprus and Mauritius. These jurisdictions serve as key hubs with a high concentration of brokers, and B2Prime is dedicated to serving regulated market participants not only in these locations but also throughout Europe. This latest license underscores B2Prime's commitment to providing trusted and compliant services to its global client base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430008885/en/
B2Prime, a globally renowned multi-asset Prime of Prime liquidity provider, has obtained a security dealer license in Seychelles, expanding its global operations and opening doors to its top-tier liquidity services for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. (Photo: Business Wire)
Seychelles, recognised as a crucial hub for brokers, provides B2Prime with a strategic platform to distribute liquidity locally across all regulated companies.
The newly acquired security dealer license enables the B2Prime group to engage in crucial financial activities, such as negotiating and entering agreements for acquiring, disposing of, subscribing for, or underwriting securities. Additionally, it allows to manage securities transactions, handle sales, and manage portfolios of securities on behalf of the clients.
This significant development will greatly enhance the ability to operate efficiently within global markets, backed by a robust legal framework to offer these services under the strict regulatory oversight of the Seychelles Financial Services Authority (SFSA).
Importance of Seychelles License for B2Prime Clients
Seychelles is becoming an attractive location for brokerages, thanks to its strategic placement between Africa, Asia, and the Middle East and its supportive financial climate. With 182 brokers already registered in Seychelles, there is a clear need for a local liquidity partner that can streamline operations and offer advanced financial and technology solutions.
In response to this demand, B2Prime has strategically expanded its presence by acquiring a security dealer license from the Seychelles Financial Services Authority (SFSA), the regulatory body responsible for the licensing and supervision of financial service providers, including security dealers.
This development eliminates the need for local companies to seek out or connect with liquidity providers in distant financial hubs. Instead, they can directly access B2Prime’s extensive Prime of Prime level liquidity.
B2Prime offers over 225 instruments across six asset classes in CFDs, including FOREX, Cryptos, Spot Indices, Precious Metals, Commodities, and NDFs, all through a single margin account. B2Prime clients benefit from deep liquidity pools sourced from Tier-1 providers, which ensure tight spreads and ultra-fast execution. Connectivity options, including OneZero, PXM, Centroid, T4B, FIX API, and cTrader, further facilitate seamless integration and efficiency.
“Establishing our operations in Seychelles opens doors to our Prime of Prime liquidity and enhanced service levels for local brokers, hedge funds, money managers, institutional clients, and liquidity providers. This step forward aligns perfectly with our goal of providing top-tier financial services worldwide and enables us to offer even greater reliability and seize new opportunities in global markets.”
– Eugenia Mykulyak, Founder & Executive Director of B2Prime
Robust Financial Performance and Future Outlook
Following the strategic initiatives, B2Prime has recently disclosed the financial results for its parent company, B2B Prime Services EU, which highlights robust financial growth in the first quarter of 2024. Total assets in Cyprus surged to €28,969,690.98, a 40.32% increase from the previous year. Client assets held for trading also increased by 47.6% to €26,840,460.11.
In the same period, the shareholders' equity rose by 8%, with year-on-year comparisons showing a 68% growth in total assets and a 64% increase in client assets held for trading. Notably, shareholders' equity experienced an impressive 289% surge. Regulatory Capital Adequacy dramatically improved, too, with B2Prime's own funds soaring nearly 600% from €503,000 to €2,728,000, far exceeding regulatory minimums with CET1 and Tier 1 ratios significantly above the required standards.
These figures highlight a strong balance sheet and show B2Prime’s ongoing devotion to growth and reliability. Soon, the company will also disclose the fiscal report for B2Prime Mauritius, which will further validate its position as a credible and reliable service provider to clients worldwide.
Final Remarks
B2Prime has been actively expanding its global footprint since its establishment in Cyprus in 2020 and Mauritius in 2023. The ongoing strategy aims to position B2Prime as a trusted partner in key financial jurisdictions worldwide. The recent acquisition of a security dealer license in Seychelles is a continuation of these efforts to offer Prime of Prime financial services and exclusive tools to local businesses in Seychelles, enhancing their capabilities and potential to succeed in the global marketplace.
The company is thrilled to start operating as a trusted liquidity provider in Seychelles and partner with local businesses!
Reach out today for market-leading liquidity solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430008885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom